⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for iressa

Every month we try and update this database with for iressa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung CancerNCT00234442
Brain Neoplasms
Non Small Cell ...
Iressa (Gefitin...
18 Years - AstraZeneca
Open-Label Extension of Other SZ1839 (Iressa) TrialsNCT00635973
Cancer
Gefitinib (Ires...
18 Years - AstraZeneca
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerNCT00317772
Ovarian Cancer
Peritoneal Neop...
Fallopian Tube ...
Topotecan
Gefitinib
- M.D. Anderson Cancer Center
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer PatientsNCT00206492
Breast Cancer
Iressa
Tamoxifen
18 Years - Baylor Breast Care Center
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerNCT00317772
Ovarian Cancer
Peritoneal Neop...
Fallopian Tube ...
Topotecan
Gefitinib
- M.D. Anderson Cancer Center
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the SkinNCT00054691
Skin Cancer
Iressa
18 Years - M.D. Anderson Cancer Center
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant MesotheliomaNCT00787410
Mesothelioma
ZD1839
18 Years - AstraZeneca
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerNCT00181688
Ovarian Cancer
Peritoneal Carc...
Tubal Carcinoma
Iressa (ZD1839)
Arimidex (Anast...
18 Years - Massachusetts General Hospital
Combination Casodex® and Iressa™ in Locally Advanced Prostate CancerNCT00319787
Locally Advance...
Iressa
18 Years - 80 YearsAstraZeneca
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer PatientsNCT00206492
Breast Cancer
Iressa
Tamoxifen
18 Years - Baylor Breast Care Center
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung CancerNCT00234442
Brain Neoplasms
Non Small Cell ...
Iressa (Gefitin...
18 Years - AstraZeneca
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck CancerNCT00681967
Head and Neck C...
Gefitinib
Gefitinib
18 Years - AstraZeneca
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)NCT00215202
Nonresectable A...
Iressa (ZD1839)
18 Years - Dartmouth-Hitchcock Medical Center
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant MesotheliomaNCT00787410
Mesothelioma
ZD1839
18 Years - AstraZeneca
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck CancerNCT00681967
Head and Neck C...
Gefitinib
Gefitinib
18 Years - AstraZeneca
Gefitinib Usage and Outcomes in Routine TreatmentNCT01818947
Lung Cancer
18 Years - AstraZeneca
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerNCT00238628
Lung Cancer
Bexarotene
Iressa
18 Years - Stanford University
Iressa Study in Patients With Salivary Gland CancerNCT00509002
Salivary Gland ...
Gefitinib
- M.D. Anderson Cancer Center
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck CancerNCT00352105
Head and Neck C...
cisplatin
fluorouracil
Iressa
hyperfractionat...
18 Years - Case Comprehensive Cancer Center
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerNCT00173875
Non-Small Cell ...
Iressa
20 Years - National Taiwan University Hospital
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaNCT00130702
Myelogenous Leu...
gefitinib
18 Years - Dana-Farber Cancer Institute
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR MutationsNCT00372515
Non-Small Cell ...
Gefitinib
18 Years - Dana-Farber Cancer Institute
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck CancerNCT00352105
Head and Neck C...
cisplatin
fluorouracil
Iressa
hyperfractionat...
18 Years - Case Comprehensive Cancer Center
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerNCT00173875
Non-Small Cell ...
Iressa
20 Years - National Taiwan University Hospital
Iressa and Taxotere Study in Patients With Metastatic Urothelial CancerNCT00479089
Bladder Cancer
Docetaxel
ZD1839
Dexamethasone
- M.D. Anderson Cancer Center
Open Label Trial to Assess Iressa in Prostate Cancer PatientsNCT00635856
Prostate Cancer
Gefitinib
18 Years - AstraZeneca
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic CancerNCT00137761
Metastatic Panc...
ZD 1839
Docetaxel
18 Years - Dana-Farber Cancer Institute
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerNCT00317772
Ovarian Cancer
Peritoneal Neop...
Fallopian Tube ...
Topotecan
Gefitinib
- M.D. Anderson Cancer Center
Iressa and Taxotere Study in Patients With Metastatic Urothelial CancerNCT00479089
Bladder Cancer
Docetaxel
ZD1839
Dexamethasone
- M.D. Anderson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: